Clinical Trials
217
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
Cord Blood Platelet Poor Plasma Eye Drops
- Conditions
- Dry Eye
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Target Recruit Count
- 100
- Registration Number
- NCT07089511
- Locations
- 🇮🇹
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
13C-Octanoic Acid Breath Test on Gastric Emptying in Celiac Patients With Functional Disorders
- Conditions
- Functional Gastrointestinal Disorders
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Target Recruit Count
- 68
- Registration Number
- NCT07089498
- Locations
- 🇮🇹
Leda Roncoroni, Milan, Italy
🇮🇹Luca Elli, Milan, Italy
EVOLVING AZIMUTH IN MUSA CONTEXT
- Conditions
- Heart FailureBlood PressureWeight ChangeTelemonitoring
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Target Recruit Count
- 184
- Registration Number
- NCT07022067
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study
- Conditions
- Peyronie DiseasePenile CurvaturePRP InjectionCord BloodRandomised Clinical TrialPenile Injection Therapy
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Target Recruit Count
- 42
- Registration Number
- NCT07010900
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study
- Conditions
- CCMFamilial Cerebral Cavernous Malformation
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 100
- Registration Number
- NCT06983132
- Locations
- 🇮🇹
Policlinico di Bari, Bari, Italy
🇮🇹Careggi Hospital, Firenze, Firenze, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Genova, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 39
- Next
News
FDA Grants IDE Approval for Newronika's Novel Adaptive Deep Brain Stimulation System for Parkinson's Disease
• Newronika has received FDA Investigational Device Exemption (IDE) approval to commence a pivotal trial evaluating their adaptive deep brain stimulation system for movement disorders, particularly Parkinson's disease. • The company's innovative AlphaDBS system utilizes real-time brain signal feedback to deliver personalized stimulation therapy, potentially offering improved outcomes over conventional DBS treatments. • The upcoming multinational pivotal trial will compare the adaptive system's performance against traditional DBS in advanced Parkinson's disease patients, marking a crucial step toward U.S. regulatory approval.